Live
Oncotype DX Breast Cancer Testing
£272,700
East Sussex Healthcare NHS TrustExact Sciences UK, Ltd.
services
Contract Details
- Tender Value
- £272,700
- Stage
- Live
- Published
- Awarded
Timeline
Awarded
Disclosed
Start
End
Description
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.
Related Contracts
From This Buyer
- Front end speech recognition - Community
£53,166 ·
- OCC Digital Capabilities
£2,500,000 ·
- Maternity EPR Solution
£166,110 ·
- Clinical Safety Services
£117,000 ·
From This Supplier
In This Category
Ref: be83749f-55db-4eb4-b59b-40aa06ac75c4-886769 · Sourced from Contracts Finder
View source notice